Skip to content

Advertisement

  • Oral presentation
  • Open Access

Efficient progerin clearance through autophagy induction and SRSF-1 downregulation in Hutchinson-Gilford Progeria Syndrome

Orphanet Journal of Rare Diseases201510(Suppl 2):O9

https://doi.org/10.1186/1750-1172-10-S2-O9

Published: 11 November 2015

Keywords

  • Skeletal Muscle
  • Point Mutation
  • Cell Nucleus
  • Related Disease
  • Accelerate Aging

Hutchinson-Gilford progeria syndrome (HGPS) is an extremely rare premature and accelerated aging disease caused by a de novo point mutation in LMNA encoding A-type lamins. Progerin, a truncated and toxic form of prelamin A, accumulates in HGPS cells nuclei and is a hallmark of the disease. We show that progerin is sequestered, together with other proteins (lamins B1/B2, emerin), into abnormally shaped nuclear organelles, identified as novel biomarkers in Progeria. We identified a novel compound that led to effective progerin degradation and clearance from patients’ fibroblasts. This compound induces progerin nucleocytoplasmic translocation, and progerin degradation through macroautophagy. It also strongly reduces progerin production through caspase-linked cleavage of SRSF-1 controlling prelamin A mRNA splicing. In vivo, upon treatment with the compound, progerin expression decreases in skeletal muscle of Lmna G609G/G609G mice. Altogether, we demonstrate increased progerin clearance based on the dual action of a novel compound and shed light on a novel promising class of molecules towards a therapy for Progeria and related diseases.

Authors’ Affiliations

(1)
Aix Marseille Université, INSERM, GMGF UMR_S 910, Marseille, France

Copyright

© Harhouri 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement